Agenus | AGEN

Stock Price
1.88
Daily Change
1.63%
Yearly
10.59%
Q2 Forecast
1.55
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Jiangsu Hengrui Me. 45.50 -0.81 -1.75% 41.79%
AbbVie 136.86 1.43 1.06% -8.30%
Agenus 1.88 0.03 1.63% 10.59%
Amgen 220.80 -0.43 -0.19% -10.06%
AstraZeneca 11,754.00 -78.00 -0.66% 14.01%
Bristol-Myers Squibb 65.12 -0.36 -0.55% -14.52%
Celldex Therapeutics 34.66 -0.32 -0.90% 44.52%
CSL 308.86 1.14 0.37% 14.01%
Dynavax Technologies 11.55 -0.12 -1.03% -7.75%
Gilead Sciences 75.91 -0.29 -0.38% 21.69%
GlaxoSmithKline 1,376.20 -15.20 -1.09% -21.40%
Glaxosmithkline 34.28 -0.35 -1.00% -22.45%
Immunogen 14.92 -0.23 -1.52% 270.22%
Incyte Corp 61.27 -0.44 -0.71% -18.30%
J&J 158.28 0.10 0.06% -10.72%
Karyopharm Therapeutics 2.35 -0.03 -1.26% -63.79%
Eli Lilly 440.62 -2.45 -0.55% 40.55%
MacroGenics 5.33 0.14 2.68% 61.01%
Merck 169.05 -1.45 -0.85% -3.95%
Merck & Co 107.75 -2.26 -2.05% 20.42%
Novartis 89.50 -1.02 -1.13% 4.34%
Novavax 7.65 0.42 5.81% -84.73%
Northwest Biotherapeutics 0.72 0.03 3.62% 2.17%
Pfizer 39.02 0.65 1.69% -27.02%
Regeneron Pharmaceuticals 743.18 -4.96 -0.66% 22.28%
Rigel Pharmaceuticals 1.51 0 0% 115.56%
Sangamo BioSciences 1.27 0.01 0.79% -70.26%
Veracyte 25.95 0.14 0.54% 39.52%
Intrexon 1.33 0.03 1.92% -13.96%

Indexes Price Day Year
USND 13150 -126.09 -0.95% 8.80%
US2000 1885 29.50 1.59% -0.32%

Agenus

Agenus traded at $1.88 this Wednesday June 7th, increasing $0.03 or 1.63 percent since the previous trading session. Looking back, over the last four weeks, Agenus gained 18.25 percent. Over the last 12 months, its price rose by 10.59 percent. Looking ahead, we forecast Agenus to be priced at 1.55 by the end of this quarter and at 1.42 in one year, according to Trading Economics global macro models projections and analysts expectations.

Agenus Inc. (Agenus) is a clinical-stage immuno-oncology (I-O) company. It has a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. Its I-O assets include antibody-based therapeutics, monospecific and bispecific antibodies, cell therapy, neoantigen cancer vaccines (individualized and off-the shelf) platforms and adjuvants. Its anti-PD-1 antibody and first-generation and next generation anti-CTLA-4 antagonists are in clinical development. Its pipeline of pre-clinical assets, which include AGEN1777, an anti-TIGIT bispecific antibody and AGEN1327, an anti-TIGIT monospecific antibody. Its neoantigen vaccine platforms include its heat shock protein (HSP) based Prophage vaccine candidates and its synthetic, neoantigen vaccine candidates, AutoSynVax (ASV) and PhosphoSynVax (PSV). Its neoantigen vaccine platforms include individualized ASV and off-the-shelf PSV, which target antigens expressed across patients and tumors.